CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Phase 1 dose-escalation study started at clinical sites in the U.S.Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseasesTÜBINGEN, GERMANY and …